Citigroup analyst James Hardiman initiates coverage on Harley-Davidson (NYSE:HOG) with a Neutral rating and announces Price Target of $40.
Needham Maintains Buy on Revance Therapeutics, Raises Price Target to $35
Needham analyst Serge Belanger maintains Revance Therapeutics (NASDAQ:RVNC) with a Buy and raises the price target from $25 to $35.